Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight loss....
- A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
- Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
- Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
- In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
- In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
- Addendum: Dexlansoprazole for GERD
The FDA has licensed PreHevbrio (VBI Vaccines), a recombinant, 3-antigen, 3-dose hepatitis B vaccine, for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults. It has been available in Israel since 2000.